AmpliPhi BioSciences Corp has appointed Scott Salka as its new chief executive, replacing interim CEO Jeremy Curnock Cook, who will remain in his role as chairman. The appointment is effective 18 May. Mr Salka is currently CEO of Aspyrian Therapeutics Inc, a company developing near-infrared photoimmunotherapies. Prior to that he was CEO of Ambit Biosciences which was acquired by Daiichi Sankyo in 2014. Mr Salka will be based in San Diego. AmpliPhi is developing bacteriophage-based antibiotics and has operations in Richmond, Virginia, US; Ljubljana, Slovenia and Sydney, Australia.
AmpliPhi BioSciences announced the appointment on 1 May 2015.
Copyright 2015 Evernow Publishing Ltd